Pelacarsen Roll-over Extension Program for Atherosclerotic Cardiovascular Disease
This study is an extension program for people who have already completed a previous study involving the drug pelacarsen (TQJ230). It aims to provide continued access to pelacarsen for participants who successfully finished one of two earlier studies. The main goal is to understand the long-term safety of taking pelacarsen 80mg once a month. You could be eligible if you are between 18 and 100 years old, have atherosclerotic cardiovascular disease (a condition where plaque builds up in your arteries), and have completed one of the parent studies. The study plans to enroll about 599 participants, but its current status is unclear.
- Study design
- This is an open-label (meaning both you and the study team know what treatment you're receiving), non-randomized extension study. It aims to enroll 599 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track adverse events (side effects) for up to 48 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pelacarsen Roll-over Extension Program
At a glance
Conditions
Where it's being run
97 sites across 21 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of Adverse events (AEs) or serious adverse events (SAEs)Up to 48 months
Evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants with elevated Lp(a) and established atherosclerotic cardiovascular disease who have completed the parent study